Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Yumeng Zhang, Daniel DeAvila, Fatima Tuz Zahra, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Leidy Isenalumhe, Lubomir Sokol, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 8017.

https://doi.org/10.1182/blood-2025-8017

Published: 2025

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Blood (2025) 146 (Supplement 1): 479.

https://doi.org/10.1182/blood-2025-479

Published: 2025

Journal Articles

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Blood (2025) 146 (Supplement 1): 471.

https://doi.org/10.1182/blood-2025-471

Published: 2025

Journal Articles

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

Chan Cheah, Mohamed Shanavas, Julio Chavez, Yanhong Tong, Xiaoyun (Nicole) Li, Prasanna Kumar, Amit Agarwal, Mary Ann Anderson, Nitin Jain

Blood (2025) 146 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2025-1839

Published: 2025

Journal Articles

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Fnu Amisha, Syeda Saba Kareem, Kiranpreet Kaur, Biwei Cao, Samuel Reynolds, Yumeng Zhang, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Javier Pinilla-Ibarz, Lubomir Sokol, Bijal Shah, Frederick Locke, Julio Chavez, Michael Jain

Blood (2025) 146 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2025-5512

Published: 2025

Journal Articles

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Abida Babu, syeda mahrukh naqvi, Julio Chavez, Bijal Shah, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Yumeng Zhang, Javier Pinilla-Ibarz, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2025-1825

Published: 2025

Journal Articles

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Nilanjan Ghosh, Julio Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam Olszewski, Seema Naik, Song Pham, Michael C. Wei, Connie L. Batlevi, Iris To, Wahib S. Ead, Sneha Makadia, Elicia Peneul, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2025-1020

Published: 2025

Journal Articles

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Manali Kamdar, Julio Chavez, Adam Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Sneha Makadia, Song Pham, Elicia Peneul, Hao Wu, Wahib S. Ead, Iris To, Dennis J. Houston, Connie Lee Batlevi, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 3735.

https://doi.org/10.1182/blood-2025-3735

Published: 2025

Journal Articles

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

Sattva Neelapu, Moshe Fridman, Mark Ray, Sally Wade, Jacob Wulff, David Cobley, Jenny Kim, Julio Chavez

Blood (2025) 146 (Supplement 1): 3717.

https://doi.org/10.1182/blood-2025-3717

Published: 2025

Journal Articles

Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy

M Bakri Hammami, Dasom (Caroline) Lee, Lindsey Raymond, Meghan Menges, Salvatore Corallo, Julieta Abraham Miranda, Bijal Shah, Julio Chavez, Aleksandr Lazaryan, Michael Jain, Frederick Locke

Blood (2025) 146 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2025-4166

Published: 2025

Journal Articles

Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era

Juan Ramirez, Daniel DeAvila, Elisa Galdamez, Cynthia Gwede, Javier Pinilla-Ibarz, Yumeng Zhang, Julio Chavez

Blood (2025) 146 (Supplement 1): 1896.

https://doi.org/10.1182/blood-2025-1896

Published: 2025

Journal Articles

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Sushmita Khadka, Anushi Patel, Jonathan Zhao, Leidy Isenalumhe, Lubomir Sokol, Sameh Gaballa, Yumeng Zhang, Celeste Bello, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2025-1882

Published: 2025

Journal Articles

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Yumeng Zhang, Jongphil Kim, Richard Corona, Shannen Whiddon, Janice Bennett, Anthony Suda, Bijal Shah, Celeste Bello, Julio Chavez, Leidy Isenalumhe, Sameh Gaballa, Javier Pinilla-Ibarz, Frank Glass, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2025-1881

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).

Timothy Shaw, Melanie Mediavilla Varela, Alyssa Obermayer, Rocco English, Xiaoqing Yu, Jose Alejandro-Guevara, Jorge Mansilla-Soto, Jose Conejo-Garcia, Paulo Rodriguez, Eva Sahakian, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 5881.

https://doi.org/10.1182/blood-2025-5881

Published: 2025

Journal Articles

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Fnu Amisha, Jessica Shostak, Wenyi Fan, Onyee Chan, Rory Shallis, Zhuoer Xie, Alison Walker, Sameh Gaballa, Javier Pinilla-Ibarz, Eric Padron, David Sallman, Bijal Shah, Julio Chavez, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Yumeng Zhang, Todd Knepper, Andrew Kuykendall

Blood (2025) 146 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2025-3531

Published: 2025

Journal Articles

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Blood (2025) 146 (Supplement 1): 468.

https://doi.org/10.1182/blood-2025-468

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy

Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only